Results 61 to 70 of about 48,812 (228)

A Case of Ipilimumab Induced Hypophysitis [PDF]

, 2015
Introduction Ipilimumab (Yervoy®) is a human monoclonal antibody that has been shown to significantly improve survival in cases of metastatic melanoma.1 Ipilimumab blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein receptor on the surface of T ...
Ukrainski, MD, Melinda, Shiffrin, MD, Eric, Eric Shiffrin, Melinda Ukrainski   +3 more
core   +1 more source

Agnostic evaluation of ipilimumab and nivolumab association : a metanalysis [PDF]

, 2020
Background: Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-lasting effect.
Marchetti P., Giannarelli D., Botticelli A., Ascierto A. P., Curigliano G.   +4 more
core   +1 more source

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Diagnostics, 2018
Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone.
Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis   +4 more
doaj   +1 more source

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Treating metastatic melanoma with ipilimumab: Clinical activity, health-related quality of life, and combination with a telomerase peptide vaccine

, 2022
Ipilimumab was the first therapy with evidenced survival benefits in patients with metastatic melanoma. Based on two clinical trials, the thesis aimed to assess the efficacy, toxicity and health-related quality of life in a real-world population with ...
Aamdal, Elin
core   +1 more source

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

, 2021
Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment.
Lyle, M., Michielin, O., Lebbe, C., Ascierto, P.A., Reijers, ILM, Betof Warner, A., Sandhu, S., Serra-Bellver, P., Zimmer, L., Patrinely, J.R., Gerard, C.L., Lorigan, P., Weppler, A.M., Lo, S.N., Menzies, A.M., Allayous, C., Stout, D., Ahmed, T., Mangana, J., Pires da Silva, I., Klein, O., Trojaniello, C., Carlino, M.S., Johnson, D.B., Long, G.V., Haydon, A., Nguyen, K., Blank, C.U.   +27 more
core   +2 more sources

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source

Ipilimumab, -omics, and head and neck cancers—update in 2025

Frontiers in Immunology
Immunotherapy employing immune checkpoint inhibitors (ICIs) represents a pivotal approach for the management of recurrent and metastatic head and neck cancers (HNCs).
Robert Kucharski, Robert Kucharski, Adam Kosiński, Adam Kosiński, Leszek Kalinowski, Leszek Kalinowski, Karolina Kaźmierczak-Siedlecka, Karolina Kaźmierczak-Siedlecka   +7 more
doaj   +1 more source

Unraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma

International Journal of Cancer, EarlyView.
ABSTRACT Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced melanoma remains challenging due to frequent treatment resistance. Resistance may be intrinsic (primary) or emerge over time (secondary). Biomarkers predicting distinct resistance phenotypes before therapy are lacking.
Julian Kött, Glenn Geidel, Carmen M. T. Roeper, Lucija Ačkar, Bente Siebels, Hannah Voß, Hartmut Schlüter, Michaela Schweizer, Kilian Müller, Alessandra Rünger, Tim Zell, Benjamin Deitert, Ali Zeinal‐Abedini, Isabel Heidrich, Stefan W. Schneider, Klaus Pantel, Daniel J. Smit, Christoffer Gebhardt   +17 more
wiley   +1 more source

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [PDF]

, 2011
Background Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma.
Thomas, Luc, Richards, Jon, Davidson, Neville, Robert, Caroline, Harmankaya, Kaan, Hoos, Axel, Weber, Jeffrey, Gascon, Pere, Ibrahim, Ramy, Francis, Stephen, O’Day, Steven, Humphrey, Rachel, Miller, Wilson H., Wolchok, Jedd D., Baurain, Jean-François, Testori, Alessandro, Grob, Jean-Jacques, Chen, Tai-Tsang, Bondarenko, Igor, Maio, Michele, Lotem, Michal, Hauschild, Axel, Garbe, Claus, Lebbe, Celeste   +23 more
core   +2 more sources